Estado del arte con el tratamiento con inhibidores de BRAF + MEK

68 / 116

MAPK pathway and BRAF mutation
NRAS
MEK 1/2
ERK 1/2
P
P phosphorylation
P
P
P
PP
P
P
P
RTK
NF-1
NRAS mutations :
20-25 % of
cutaneous melanoma
BRAF
P
Vemurafenib
Dabrafenib
Encorafenib
NF-1 mutations :
15-20% of
cutaneous
melanoma
BRAF mutations :
40-50% of
cutaneous
melanoma
↑ cell proliferation
and cell survival
Adapted from: Koeblinger et al. Future Oncology, 2017